SC7 - Secure societies – Protecting freedom and security of Europe and its citizens

About this programme

This Societal Challenge is about undertaking the research and innovation activities needed to protect the European citizens, society and economy as well as the infrastructures services, the prosperity, political stability and wellbeing.

The work programme of 2018-2020 focuses on protecting the infrastructure of Europe, security and digital security.

This is translated into the following subjects:

  • Protecting the infrastructure of Europe and the people in European smart cities
  • Disaster-resilient societies
  • Fight against crime and terrorism
  • Border and external security
  • Cybersecurity, digital privacy and data protection
  • Management of cyber-attacks and other risks
Click to read more 
Hide text 

Your NCP contacts for this programme

No dedicated person at the moment

Please contact

info@ncpflanders.be

+32 2 550 15 65

Your PC contact for this programme

Find the contact info on the site of WEWIS

The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.

The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.

Latest news

Upcoming events

No events that are specifically related to SC7 - Secure societies – Protecting freedom and security of Europe and its citizens were found. Check the full calendar.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.